The data are clear: White patients are taking up the majority of clinical trials.
About 130 million Americans across various races are “being somewhat ignored, [or] deprioritized, in clinical trials” that support regulatory approval, said Yele Aluko, M.D., chief medical officer for EY Americas, in a November Fierce Biotech interview. That’s “embarrassing,” Aluko added.
We also know for sure that drug developers and their partners need to include more races and women in studies of their medicines because side effects and treatment effectiveness aren’t universal.
